Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of October 2024. The report serves as a notification to the market regarding the Company's total voting rights and capital structure as of September 30, 2024, in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital and voting rights data.
| Metric | Value as of Sept 30, 2024 |
|---|---|
| Issued Share Capital | 4,314,258,970 Ordinary Shares (31.25 pence each) |
| Treasury Shares | 169,171,155 Ordinary Shares |
| Total Voting Rights | 4,145,087,815 |
Material Changes
The filing text does not provide a clear value for material changes versus the prior comparable period. The document presents a static snapshot of share capital and voting rights without comparative historical data.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The report is a regulatory notification intended to assist shareholders in calculating disclosure thresholds under FCA rules.
Investor Verification Checklist
- Verify the total number of voting rights (4,145,087,815) to determine if disclosure thresholds under FCA rules have been met.
- Confirm the number of shares held in Treasury (169,171,155) when calculating net outstanding shares.
- Check the Company Secretary contact (company.secretary@gsk.com) for submitting interest notifications.